These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Rational selection of immunodominant and preserved epitope Sm043300e from Schistosoma mansoni and design of a chimeric molecule for biotechnological purposes. de Souza C; Lopes MD; De Oliveira FM; Passos MJF; Ferreira LCG; Faria BF; Villar JAFP; Junior MC; Taranto AG; Dos Santos LL; Fonseca CT; de Oliveira Lopes D Mol Immunol; 2018 Jan; 93():133-143. PubMed ID: 29175593 [TBL] [Abstract][Full Text] [Related]
24. Intradermal immunization of rats with plasmid DNA encoding Schistosoma mansoni 28 kDa glutathione S-transferase. Dupré L; Poulain-Godefroy O; Ban E; Ivanoff N; Mekranfar M; Schacht AM; Capron A; Riveau G Parasite Immunol; 1997 Nov; 19(11):505-13. PubMed ID: 9427997 [TBL] [Abstract][Full Text] [Related]
25. Schistosoma mansoni shares a protective carbohydrate epitope with keyhole limpet hemocyanin. Grzych JM; Dissous C; Capron M; Torres S; Lambert PH; Capron A J Exp Med; 1987 Mar; 165(3):865-78. PubMed ID: 2434601 [TBL] [Abstract][Full Text] [Related]
26. Synthesis and characterization of a protective peptide-based vaccine against Schistosoma mansoni. Tarrab-Hazdai R; Schechtman D; Arnon R Infect Immun; 1998 Sep; 66(9):4526-30. PubMed ID: 9712813 [TBL] [Abstract][Full Text] [Related]
27. A Schistosoma mansoni fatty acid-binding protein, Sm14, is the potential basis of a dual-purpose anti-helminth vaccine. Tendler M; Brito CA; Vilar MM; Serra-Freire N; Diogo CM; Almeida MS; Delbem AC; Da Silva JF; Savino W; Garratt RC; Katz N; Simpson AS Proc Natl Acad Sci U S A; 1996 Jan; 93(1):269-73. PubMed ID: 8552619 [TBL] [Abstract][Full Text] [Related]
28. Induction of protective immunity against Schistosoma mansoni by vaccination with schistosome paramyosin (Sm97), a nonsurface parasite antigen. Pearce EJ; James SL; Hieny S; Lanar DE; Sher A Proc Natl Acad Sci U S A; 1988 Aug; 85(15):5678-82. PubMed ID: 3135553 [TBL] [Abstract][Full Text] [Related]
29. Intranasal administration of synthetic recombinant peptide-based vaccine protects mice from infection by Schistosoma mansoni. Ben-Yedidia T; Tarrab-Hazdai R; Schechtman D; Arnon R Infect Immun; 1999 Sep; 67(9):4360-6. PubMed ID: 10456875 [TBL] [Abstract][Full Text] [Related]
30. DNA Vaccine Encoding the Chimeric Form of Schistosoma mansoni Sm-TSP2 and Sm29 Confers Partial Protection against Challenge Infection. Gonçalves de Assis NR; Batistoni de Morais S; Figueiredo BC; Ricci ND; de Almeida LA; da Silva Pinheiro C; Martins Vde P; Oliveira SC PLoS One; 2015; 10(5):e0125075. PubMed ID: 25942636 [TBL] [Abstract][Full Text] [Related]
31. Induction of cytotoxic T-cell activity by the protective antigen of Schistosoma mansoni Sm28GST or its derived C-terminal lipopeptide. Pancré V; Gras-Masse H; Delanoye A; Herno J; Capron A; Auriault C Scand J Immunol; 1996 Nov; 44(5):485-92. PubMed ID: 8947600 [TBL] [Abstract][Full Text] [Related]
32. Helper T cells induced by a purified 28-kilodalton antigen of Schistosoma mansoni protect rats against infection. Auriault C; Balloul JM; Pierce RJ; Damonneville M; Sondermeijer P; Capron A Infect Immun; 1987 May; 55(5):1163-9. PubMed ID: 2952594 [TBL] [Abstract][Full Text] [Related]
33. Identification of immunodominant epitopes of Schistosoma mansoni vaccine candidate antigens using human T cells. Fonseca CT; Cunha-Neto E; Kalil J; Jesus AR; Correa-Oliveira R; Carvalho EM; Oliveira SC Mem Inst Oswaldo Cruz; 2004; 99(5 Suppl 1):63-6. PubMed ID: 15486637 [TBL] [Abstract][Full Text] [Related]
34. Longevity of Sm-p80-specific antibody responses following vaccination with Sm-p80 vaccine in mice and baboons and transplacental transfer of Sm-p80-specific antibodies in a baboon. Zhang W; Ahmad G; Le L; Rojo JU; Karmakar S; Tillery KA; Torben W; Damian RT; Wolf RF; White GL; Carey DW; Carter D; Reed SG; Siddiqui AA Parasitol Res; 2014 Jun; 113(6):2239-50. PubMed ID: 24728521 [TBL] [Abstract][Full Text] [Related]
35. Immunization with Schistosoma mansoni 22.6 kDa antigen induces partial protection against experimental infection in a recombinant protein form but not as DNA vaccine. Pacífico LG; Fonseca CT; Chiari L; Oliveira SC Immunobiology; 2006; 211(1-2):97-104. PubMed ID: 16446174 [TBL] [Abstract][Full Text] [Related]
36. Schistosome vaccines: current progress and future prospects. Sher A; James SL; Correa-Oliveira R; Hieny S; Pearce E Parasitology; 1989; 98 Suppl():S61-8. PubMed ID: 2498828 [TBL] [Abstract][Full Text] [Related]